Download PDF
Adipositas - Ursachen, Folgeerkrankungen, Therapie 2016; 10(04): 207-214
DOI: 10.1055/s-0037-1617716
Übersichtsarbeit
Schattauer GmbH

Adipositas und Hypogonadismus

Resultate der Testosteron-TherapieObesity and hypogonadismResults from testosterone therapy
F. Saad
1   Global Medical Affairs Andrologie, Bayer Pharma AG, Berlin und Gulf Medical University,Ajman, VAE
› Author Affiliations
Further Information

Publication History

Publication Date:
29 December 2017 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Bei adipösen Männern mit Testosteronmangel führt eine Testosteron-Therapie (TTh) zur deutlichen Verbesserung der anthropometrischen Parameter. Bemerkenswert sind dabei vor allem Kontinuität und Nachhaltigkeit der Gewichtsreduktion über Beobachtungszeiträume von bis zu acht Jahren. Unter der TTh kommt es ferner zu einer Rückführung der metabolischen Parameter in Richtung Normbereich, so dass gerade für die häufig auftretende Kombination von Adipositas, metabolischem Syndrom, Diabetes und Herz-Kreislauferkrankungen ein wesentlicher Grundstein für eine Verbesserung des Gesundheitszustands gelegt wird.

Summary

Obese, hypogonadal men under testosterone therapy show a substantial improvement of their anthropometric parameters. In particular the continuity and sustainability of the weight reduction must be noted which could be shown during treatment periods of up to eight years. Moreover, under testosterone therapy the metabolic parameters are substantially improved. For the frequent combination of obesity, metabolic syndrome, diabetes and cardiovascular diseases this represents a suitable basis to gain an improved health status.

Schlüsselwörter

Hypogonadismus - Adipositas - Testosteron-Therapie

Keywords

Hypogonadism - obesity - testosterone therapy
 

  • Literatur

  • 1 Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. The Journal of Clinical Endocrinology & Metabolism 2007; 92 (11) 4241-4247.
    CrossrefPubMedGoogle Scholar
  • 2 Araujo AB, Wittert GA. Endocrinology of the aging male. Best Practice & Research Clinical Endocrinology & Metabolism 2011; 25 (02) 303-319.
    CrossrefPubMedGoogle Scholar
  • 3 Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with lateonset hypogonadism and metabolic syndrome: results from a 24-months, randomized, doubleblind, placebo-controlled study. The Journal of Sexual Medicine 2010; 07: 3495-3503.
    CrossrefPubMedGoogle Scholar
  • 4 Bair TL, May H, Le VT, Lappe D, Anderson J, Muhlestein J. Clinical effects of testosterone supplementation among hypo-androgenic men with preexisting severe coronary artery disease: the intermountain heart collaborative study. Journal of the American College of Cardiology. 2016 67. (13_S): 2097.
    PubMedGoogle Scholar
  • 5 Behre HM, Tammela TLJ, Arver S, Tolrá JR, Bonifacio V, Lamche M, Kelly J, Hiemeyer F, Giltay EJ, Gooren LJ. A randomized, double-blind, placebocontrolled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label followup. The Aging Male 2012; 15 (04) 198-207.
    CrossrefPubMedGoogle Scholar
  • 6 Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. The Journal of Clinical Endocrinology & Metabolism 2005; 90 (02) 678-688.
    CrossrefPubMedGoogle Scholar
  • 7 Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, Wang PY, Nielson C, Wu F, Tajar A, Labrie F, Vesper H, Zhang A, Ulloor J, Singh R, D’Agostino R, Vasan RS. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. The Journal of Clinical Endocrinology & Metabolism 2011; 96 (08) 2430-2439.
    CrossrefPubMedGoogle Scholar
  • 8 Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opinion of Pharmacotherapy 2014; 15 (13) 1903-1926.
    PubMedGoogle Scholar
  • 9 Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism 2004; 89: 5462-5468.
    CrossrefPubMedGoogle Scholar
  • 10 Dohle GR, Arver S, Bettocchi C, Kliesch S, Punab M, de Ronde W. Leitlinie Männlicher Hypogonadismus. Journal für Reproduktionsmedizin und Endokrinologie 2013; 10 5-6 279-292.
    PubMedGoogle Scholar
  • 11 Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M. Guidelines on male hypogonadism. EAU Guidelines. 2015
    PubMedGoogle Scholar
  • 12 Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014; 83 (01) 167-174.
    CrossrefPubMedGoogle Scholar
  • 13 Francomano D, Lenzi A, Aversa A. Effects of fiveyear treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. International Journal of Endocrinology. 2014 2014. Article ID 527470.
    PubMedGoogle Scholar
  • 14 Free & bioavailable testosterone calculator. http://www.issam.ch/freetesto.htm
    PubMed
  • 15 Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with “diabesity”: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. International Journal of Endocrinology. 2014 2014. Article ID 683515.
    PubMedGoogle Scholar
  • 16 Haider A, Yassin A, Haider KS, Doros G, Saad F, Rosano GMC. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vascular Health and Risk Management 2016; 12: 251-261.
    PubMedGoogle Scholar
  • 17 Haring R, Ittermann T, Völzke H, Krebs A, Zygmunt M, Felix SB, Grabe HJ, Nauck M, Wallaschofski H. Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania. The Aging Male 2010; 13 (04) 247-257.
    CrossrefPubMedGoogle Scholar
  • 18 Jockenhövel F. Androgenmangel des älteren Mannes - Was bringt die Testosteron-Substitution?. Deutsche Medizinische Wochenschrift 2001; 126 (09) 247-252.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Kelly DM, Jones TH. Testosterone and obesity. Obesity Reviews 2015; 16: 581-606.
    CrossrefPubMedGoogle Scholar
  • 20 Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27 (05) 1036-1041.
    CrossrefPubMedGoogle Scholar
  • 21 Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, Morgentaler A. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. The Aging Male 2015; 18 (01) 5-15.
    CrossrefPubMedGoogle Scholar
  • 22 Mock K, Lunglmayr G. Androgene und Östrogene beim alternden Mann. Journal für Urologie und Urogynäkologie 1999; 06 (S2): 5-9.
    PubMedGoogle Scholar
  • 23 Nedogoda SV, Barykina IN, Salasyuk AS, Smirnova VO, Khripaeva VJ. Effects of testosterone replacement therapy on cardio-metabolic, hormonal and anthropometric parameters in obese hypogonadal men with metabolic syndrome. Obesity. 2015 01. (2) doi http://dx.doi.org/10.16966/2380-5528.108
    CrossrefPubMedGoogle Scholar
  • 24 Paasch U, Glander HJ, Stolzenburg JU. Andro- logische Testosteronersatztherapie. Der Urologe 2009; 48 (01) 79-87.
    CrossrefPubMedGoogle Scholar
  • 25 Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011; 165: 675-685.
    CrossrefPubMedGoogle Scholar
  • 26 Saad F, Yassin A, Doros G, Haider A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity class I-III: observational data from two registry studies. Int J Obes 2016; 40: 162-170.
    CrossrefPubMedGoogle Scholar
  • 27 Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impotence Research 2008; 20: 378-387.
    PubMedGoogle Scholar
  • 28 Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean MEJ, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FCW. EMAS Group Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. The Journal of Clinical Endocrinology & Metabolism 2010; 95 (04) 1810-1818.
    CrossrefPubMedGoogle Scholar
  • 29 Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clinical Practice 2014; 68 (03) 314-329.
    CrossrefPubMedGoogle Scholar
  • 30 Travison TG, Araujo AB, Kupelian V, O’Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. The Journal of Clinical Endocrinology & Metabolism 2007; 92 (02) 549-555.
    CrossrefPubMedGoogle Scholar
  • 31 Vermeulen A. Ageing, hormones, body composition, metabolic effects. World Journal of Urology 2002; 20 (01) 23-27.
    CrossrefPubMedGoogle Scholar
  • 32 WHO Europa. Adipositas: Eine Herausforderung für die Europäische Region der WHO. Faktenblatt EURO/13/05. Kopenhagen, Bukarest, 12. September 2005. http://www.euro.who.int/data/assets/pdf_file/0020/102386/fs1305g.pdf
    PubMedGoogle Scholar
  • 33 Winter A, Marte A, Kelly M, Funaro M, Schlegel P, Paduch D. Predictors of poor response to transdermal testosterone therapy in men with metabolic syndrome. The Journal of Urology 2014; 191 (4, Supplement): e528.
    PubMedGoogle Scholar
  • 34 Wu FCW, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean MEJ, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT. Identification of late-onset hypogonadism in middle-aged and elderly men. NEJM 2010; 363 (02) 123-135.
    CrossrefPubMedGoogle Scholar
  • 35 Zitzmann M. Die Therapie des Hypogonadismus des Mannes. Der Internist 2008; 49 (05) 559-569.
    CrossrefPubMedGoogle Scholar